

Katerina Chatzidionysiou

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3673616/katerina-chatzidionysiou-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

3,432
citations

19
h-index

58
g-index

63
ext. papers

4,179
ext. citations

4.9
avg, IF

4.75
L-index

#	Paper	IF	Citations
57	Effectiveness of baricitinib and tofacitinib compared to bDMARDs in RA: results from a cohort study using nationwide Swedish register data.. <i>Rheumatology</i> , 2022 ,	3.9	1
56	Comparison of immune checkpoint inhibitor-induced arthritis and reactive arthritis to inform therapeutic strategy.. <i>Biomedicine and Pharmacotherapy</i> , 2022 , 148, 112687	7.5	0
55	Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1512-1518	4.1	3
54	Tocilizumab decreases T cells but not macrophages in the synovium of patients with rheumatoid arthritis while it increases the levels of serum interleukin-6 and RANKL. <i>RMD Open</i> , 2021 , 7,	5.9	1
53	Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?. <i>Clinical Rheumatology</i> , 2021 , 40, 1687-1693 ^{3.9}	3.9	5
52	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	37
51	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. <i>RMD Open</i> , 2021 , 7,	5.9	1
50	Could severe COVID-19 be considered a complementopathy?. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	3
49	Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
48	Beyond Methotrexate and Biologics in RA - Efficacy of JAK Inhibitors and their Place in the Current Treatment Armamentarium. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 120-128	1.4	2
47	The Rheumatologist's Role in the Battle Against COVID-19: Insights from the Front Line and Challenges for the Future. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 247-252	1.4	0
46	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 87-91	1.4	0
45	Mediterranean Journal of Rheumatology March 2020 Highlights. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 1-2	1.4	
44	Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 304-307	2.4	12
43	Lung cancer in rheumatoid arthritis. Is there a need for better risk assessment and screening?. <i>Clinical Rheumatology</i> , 2020 , 39, 957-961	3.9	3
42	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. <i>RMD Open</i> , 2020 , 6,	5.9	5
41	Association between number and type of different ACPA fine specificities with lung abnormalities in early, untreated rheumatoid arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	6

40	Response to: Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus by Chatzidionysiou, von Betulin. <i>Annals of the Rheumatic Diseases</i> , 2020 , 12, 1759720X20976975	2.4	1
39	Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20976975	3.8	9
38	Validation of new classification criteria of rheumatoid arthritis in an international multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 841-847	2.2	1
37	Protective Effect of the Pro582Ser Polymorphism on Severe Diabetic Retinopathy. <i>Journal of Diabetes Research</i> , 2019 , 2019, 2936962	3.9	12
36	Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 2170-2176	3.9	18
35	Definitions of remission in systemic lupus erythematosus: a post-hoc analysis of two randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e163-e173	14.2	9
34	Rheumatic disease and artistic creativity. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 103-109	1.4	3
33	Established rheumatoid arthritis - Redefining the concept. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019 , 33, 101476	5.3	4
32	Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift. <i>RMD Open</i> , 2019 , 5, e000993	5.9	13
31	Clinical SLEDAI-2K zero may be a pragmatic outcome measure in SLE studies. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 157-168	5.4	14
30	Established organ damage reduces belimumab efficacy in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1006-1007	2.4	6
29	Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 17-23	1.9	4
28	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 476-479	2.4	45
27	Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 131-140	1.9	4
26	Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 465-474	1.9	15
25	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. <i>RMD Open</i> , 2018 , 4, e000655	5.9	11
24	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000287	4.6	7
23	Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration. <i>Journal of Rheumatology</i> , 2017 , 44, 162-169	4.1	13

22	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1113-1136	2.4	143
21	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-977	4	1649
20	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017 , 4, e000192	4.6	34
19	Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1102-1107	2.4	85
18	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1101-1136	2.4	213
17	Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 230-6	3.9	16
16	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016 , 18, 251	5.7	114
15	Optimizing biological treatments for rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 2016 , 45, 64-75	1.9	
14	Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. <i>Arthritis Research and Therapy</i> , 2016 , 18, 50	5.7	27
13	Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials. <i>RMD Open</i> , 2016 , 2, e000323	5.9	11
12	Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1336-42	2.4	47
11	A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. <i>RMD Open</i> , 2016 , 2, e000133	5.9	25
10	Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. <i>Scandinavian Journal of Rheumatology</i> , 2015 , 44, 431-7	1.9	20
9	Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 890-6	2.4	52
8	Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. <i>Scandinavian Journal of Rheumatology</i> , 2013 , 42, 190-5	1.9	37
7	Latest developments in the treatment of rheumatoid arthritis: is there new hope for patients?. <i>Clinical Practice (London, England)</i> , 2013 , 10, 233-236	3	
6	Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. <i>Lancet, The</i> , 2012 , 379, 1712-20	4.0	149
5	Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 374-7	2.4	52

4	When to initiate and discontinue biologic treatments for rheumatoid arthritis?. <i>Journal of Internal Medicine</i> , 2011 , 269, 614-25	10.8	17
3	Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1575-80	2.4	157
2	Delays in assessment of patients with rheumatoid arthritis: variations across Europe. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1822-5	2.4	88
1	Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. <i>Lancet, The</i> , 2009 , 374, 459-66	40	223